Eribulin-gemcitabine combination therapy shows promise in soft-tissue sarcomas
Eribulin in combination with gemcitabine demonstrated promising activity and appeared safe in patients with liposarcoma or leiomyosarcoma, according to results of a phase II clinical trial.
In this study, 37 patients with progressive disease previously treated with 1 or 2 courses of chemotherapy (including doxorubicin) received eribulin (1.4 mg/m2) and gemcitabine (1,000 mg/m2) on days 1 and 8, every 3 weeks. The primary endpoint was progression-free survival rate at 12 weeks (PFSR12wks), with null and alternative hypotheses of PFSR12wks {less than or equal to} 20.0% and {greater than or equal to} 40.0%, respectively.
The primary endpoint was met with an overall PFSR12wks of 73%. The objective response rate was 16.2%, disease control rate was 78.4%, median progression-free survival was 5.6 months, and median overall survival was 31.9 months, without differences according to histologic type.
The safety profile was considered acceptable with no new documented safety signals or treatment-related deaths.
Next-generation sequencing performed on pretreatment tumor samples found that functional enrichment in the transforming growth factor-ß pathway was mostly associated with poor outcomes.
Reference
Kim CG, Sim NS, Kim JE, et al. Phase II clinical trial of Eribulin-gemcitabine combination therapy in previously treated patients with advanced liposarcoma or leiomyosarcoma. Clin Cancer Res. 2022;clincanres.CCR-22-0518-E.2022. doi: 10.1158/1078-0432.CCR-22-0518. Epub ahead of print. PMID: 35583824.
